Company intelligence / Profile preview

Renovion

Chapel Hill, North Carolina, United States

Ownership: Private
Development stage: Phase 3

Overview

Renovion recently announced positive top-line results from Phase 2 CLIMB study of ARINA-1 (RVN-301) in patients with Non-Cystic Fibrosis Bronchiectasis on May 2, 2024. The study showed improved quality of life and mucus biomarkers in bronchiectasis patients. The company is also conducting a Phase 3 trial for ARINA-1 in lung transplant patients with BOS.

Therapeutic areas: Pulmonology
Modalities: Nebulized therapy
Industry: Biotech

Drug pipeline

1 asset

ARINA-1

Partnerships

COPD Foundation

Beyond the preview

Go deeper on Renovion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renovion.

Explore the full profile